Rethinking Treatment of Heart Failure
Left Atrial Pressure:
A novel therapeutic target.
Heart failure accounts for over 1 million hospitalizations each year and over $35B in direct annual costs. As our population ages, the disease burden is expected to rise dramatically.
At Alleviant Medical, we're developing a minimally-invasive, transcatheter device to treat congestive heart failure by targeting pressure buildup within the left atrium — the key driver of heart failure symptoms.
Our proprietary technology is intended to create a paradigm-shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americans currently suffering from this condition.
Meet Our Team
We combine over 30 years of experience in healthcare, technology, and design.
The Alleviant Medical team is a dynamic group of co-founders and innovators committed to developing a transformative technology that will enable heart failure patients to get the right care at the right time.
Scientific / Technical Advisory Board
Our advisors bring relevant clinical and industry expertise as prominent thought leaders in the fields of interventional cardiology, cardiovascular surgery, and medical devices to guide the development of our proprietary technology.
Communities & Partners
Alleviant Medical in the News
See what others are saying about our technology.
@alleviant on twitter:
Have any questions? Drop us a line using our form or email us.
TMCx+ and JLABS at TMC
2450 Holcombe Blvd, Suite X
Houston, TX 77021
21 Drydock Ave 610E
Boston, MA 02210